The role of microRNAs in prostate cancer migration, invasion, and metastasis

被引:54
作者
Aghdam, Shirin Golabi [1 ]
Ebrazeh, Mehrdad [2 ]
Hemmatzadeh, Maryam [1 ,3 ]
Seyfizadeh, Narges [4 ]
Shabgah, Arezoo Gowhari [5 ]
Azizi, Gholamreza [6 ,7 ]
Ebrahimi, Negin [1 ]
Babaie, Farhad [8 ]
Mohammadi, Hamed [1 ]
机构
[1] Tabriz Univ Med Sci, Sch Med, Dept Immunol, Tabriz 516615731, Iran
[2] Urmia Univ Med Sci, Shahid Motahari Hosp, Dept Lab Med, Orumiyeh, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[4] Heidelberg Univ Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Mashhad Univ Med Sci, Immunol Res Ctr, Mashhad, Razavi Khorasan, Iran
[6] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran
[7] Alborz Univ Med Sci, Sch Med, Dept Immunol, Karaj, Iran
[8] Urmia Univ Med Sci, Cellular & Mol Res Ctr, Orumiyeh, Iran
关键词
invasion; microRNA; migration; prostate cancer; therapy; EPITHELIAL-MESENCHYMAL TRANSITION; SUPPRESSES CELL-PROLIFERATION; TUMOR-SUPPRESSOR; DOWN-REGULATION; CIRCULATING MICRORNAS; BIOCHEMICAL RECURRENCE; EXPRESSION SIGNATURE; ANDROGEN RECEPTOR; DIAGNOSTIC BIOMARKERS; SERUM MICRORNAS;
D O I
10.1002/jcp.27948
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Prostate cancer (PCa) is considered the most prevalent malignancy and the second major cause of cancer-related death in males from Western countries. PCa exhibits variable clinical pictures, ranging from dormant to highly metastatic cancer. PCa suffers from poor prognosis and diagnosis markers, and novel biomarkers are required to define disease stages and to design appropriate therapeutic approach by considering the possible genomic and epigenomic differences. MicroRNAs (miRNAs) comprise a class of small noncoding RNAs, which have remarkable functions in cell formation, differentiation, and cancer development and contribute in these processes through controlling the expressions of protein-coding genes by repressing translation or breaking down the messenger RNA in a sequence-specific method. miRNAs in cancer are able to reflect informative data about the current status of disease and this might benefit PCa prognosis and diagnosis since that is concerned to PCa patients and we intend to highlight it in this paper.
引用
收藏
页码:9927 / 9942
页数:16
相关论文
共 160 条
[1]   The physiology and pathology of the EMT - Meeting on the epithelial-mesenchymal transition [J].
Acloque, Herve ;
Thiery, Jean Paul ;
Nieto, M. Angela .
EMBO REPORTS, 2008, 9 (04) :322-326
[2]   Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer [J].
Agaoglu, Fulya Yaman ;
Kovancilar, Muge ;
Dizdar, Yavuz ;
Darendeliler, Emin ;
Holdenrieder, Stefan ;
Dalay, Nejat ;
Gezer, Ugur .
TUMOR BIOLOGY, 2011, 32 (03) :583-588
[3]   Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer [J].
Ahmad, I. ;
Singh, L. B. ;
Yang, Z. H. ;
Kalna, G. ;
Fleming, J. ;
Fisher, G. ;
Cooper, C. ;
Cuzick, J. ;
Berney, D. M. ;
Moller, H. ;
Scardino, P. ;
Leung, H. Y. .
BRITISH JOURNAL OF CANCER, 2013, 108 (01) :149-154
[4]   Blood-based microRNAs as diagnostic biomarkers to discriminate localized prostate cancer from benign prostatic hyperplasia and allow cancer-risk stratification [J].
Al-Kafaji, Ghada ;
Said, Harun Muayad ;
Alam, Mahmood Abduljalil ;
Al Naieb, Ziad Tarraq .
ONCOLOGY LETTERS, 2018, 16 (01) :1357-1365
[5]   miR-218 Suppresses Nasopharyngeal Cancer Progression through Downregulation of Survivin and the SLIT2-ROBO1 Pathway [J].
Alajez, Nehad M. ;
Lenarduzzi, Michelle ;
Ito, Emma ;
Hui, Angela B. Y. ;
Shi, Wei ;
Bruce, Jeff ;
Yue, Shijun ;
Huang, Shao H. ;
Xu, Wei ;
Waldron, John ;
O'Sullivan, Brian ;
Liu, Fei-Fei .
CANCER RESEARCH, 2011, 71 (06) :2381-2391
[6]   Circulating microRNA signature for the diagnosis of very high-risk prostate cancer [J].
Alhasan, Ali H. ;
Scott, Alexander W. ;
Wu, Jia J. ;
Feng, Gang ;
Meeks, Joshua J. ;
Thaxton, C. Shad ;
Mirkin, Chad A. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (38) :10655-10660
[7]   Genomic profiling of MicroRNA and messenger RNA reveals deregulated MicroRNA expression in prostate cancer [J].
Ambs, Stefan ;
Prueitt, Robyn L. ;
Yi, Ming ;
Hudson, Robert S. ;
Howe, Tiffany M. ;
Petrocca, Fabio ;
Wallace, Tiffany A. ;
Liu, Chang-Gong ;
Volinia, Stefano ;
Calin, George A. ;
Yfantis, Harris G. ;
Stephens, Robert M. ;
Croce, Carlo M. .
CANCER RESEARCH, 2008, 68 (15) :6162-6170
[8]  
Bader A. G., 2012, FRONT GENET, V3, P3, DOI DOI 10.3389/FGENE.2012.00120
[9]   Nanoparticles and targeted drug delivery in cancer therapy [J].
Bahrami, Behdokht ;
Hojjat-Farsangi, Mohammad ;
Mohammadi, Hamed ;
Anvari, Enayat ;
Ghalamfarsa, Ghasem ;
Yousefi, Mehdi ;
Jadidi-Niaragh, Farhad .
IMMUNOLOGY LETTERS, 2017, 190 :64-83
[10]   Active Surveillance for Low-risk Prostate Cancer: Developments to Date [J].
Bangma, Chris H. ;
Valdagni, Riccardo ;
Carroll, Peter R. ;
van Poppel, Hein ;
Klotz, Laurence ;
Hugosson, Jonas .
EUROPEAN UROLOGY, 2015, 67 (04) :646-648